Boardroom Alpha
Boardroom Alpha
VREX · Current Report (Form 8-K) · Filed February 13, 2026

Varex Imaging Corp — Current Report (Form 8-K)

Form
8-K
Filed
February 13, 2026
Period
Feb 12, 2026
Ticker
VREX
Accession
0001681622-26-000031
Boardroom Alpha · Filing insights

Shareholders elected seven directors to serve until 2027, approved executive compensation on an advisory basis, and ratified Deloitte as the independent auditor.

About Varex Imaging Corp
Market cap
$419M
1Y TSR
+26.7%
3Y TSR
−23.0%
Board grade
B-
Sector
Healthcare
CEO
Sunny Sanyal
Last annual meeting: Feb 12, 2026 · View full Varex Imaging Corp profile →
vrex-20260212

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  ___________________________________
FORM 8-K
 ___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2026
  ___________________________________
VAREX IMAGING CORPORATION
(Exact name of registrant as specified in its charter)
 ___________________________________
Delaware
(State or other jurisdiction of incorporation or organization)
001-37860
81-3434516
(Commission File Number)
(I.R.S. Employer
Identification Number)
1678 S. Pioneer Road, Salt Lake City, Utah
84104
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (801) 972-5000
Not Applicable
(Former name or former address, if changed since last report)
 ___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockVREXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b - 2 of the Securities Exchange Act of 1934. Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.07    Submission of Matters to a Vote of Security Holders
The Annual Meeting of the Company was held on February 12, 2026. At the Annual Meeting, a total of 38,575,226 shares of Company common stock, representing approximately 92% of the shares outstanding and eligible to vote and constituting a quorum, were represented in person or by valid proxies. The final results for the votes of the Annual Meeting regarding each proposal voted on at the Annual Meeting are set forth in the following tables. Each of these proposals is described in detail in the Proxy Statement.
Proposal One:

The Company’s stockholders elected Kathleen L. Bardwell, Jocelyn D. Chertoff, Timothy E. Guertin, Jay K. Kunkel, Walter M Rosebrough, Jr., Sunny S. Sanyal and Christine A. Tsingos to serve as directors until the 2027 Annual Meeting of Stockholders:
For
Against
Abstain
Broker Non-Votes
Kathleen L. Bardwell
34,831,822167,687157,6523,418,065
Jocelyn D. Chertoff
34,075,161925,048156,9523,418,065
Timothy E. Guertin
33,765,5801,233,864157,7173,418,065
Jay K. Kunkel
34,100,816894,725161,6203,418,065
Walter M Rosebrough, Jr.
34,106,635889,066161,4603,418,065
Sunny S. Sanyal
34,822,559175,719158,8833,418,065
Christine A. Tsingos
34,826,622172,887157,6523,418,065

Proposal Two:

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement:
For
Against
Abstain
Broker Non-Votes
33,985,9131,004,141167,1073,418,065

Proposal Three:

The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year 2026:
For
Against
Abstain
38,106,353301,360167,513







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VAREX IMAGING CORPORATION
Dated: February 13, 2026
By:/s/ Matthew A. Martinez
Matthew A. Martinez
Chief Legal Officer and Corporate Secretary


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Varex Imaging Corp (VREX)

Reference

Frequently asked questions

When did Varex Imaging Corp file this 8-K?
Varex Imaging Corp (VREX) filed this Current Report (Form 8-K) with the SEC on February 13, 2026. The accession number assigned by EDGAR is 0001681622-26-000031.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders elected seven directors to serve until 2027, approved executive compensation on an advisory basis, and ratified Deloitte as the independent auditor. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Varex Imaging Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Varex Imaging Corp has filed under CIK 1681622, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer